Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$232 Mln
P/E Ratio
--
P/B Ratio
0.44
Industry P/E
--
Debt to Equity
0.02
ROE
-0.16 %
ROCE
-15.58 %
Div. Yield
0 %
Book Value
1.18
EPS
-0.2
CFO
$-627.25 Mln
EBITDA
$-519.79 Mln
Net Profit
$-640.29 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Amarin (AMRN)
| 6.49 | 17.33 | -12.86 | -40.96 | -42.94 | -41.93 | -13.00 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Amarin (AMRN)
| -43.99 | -28.10 | -64.09 | -31.08 | -77.19 | 57.53 | 237.15 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a... prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland. Address: One Central Plaza, Dublin 2, Ireland, D02 K7K5 Read more
President, CEO & Director
Mr. Patrick J. Holt
President, CEO & Director
Mr. Patrick J. Holt
Headquarters
Dublin 2
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Amarin Corporation plc (AMRN) stood at $ 685 Mln as on 31-Dec-24
The share price of Amarin Corporation plc (AMRN) is $10.33 (NASDAQ) as of 29-Apr-2025 16:21 EDT. Amarin Corporation plc (AMRN) has given a return of -42.94% in the last 3 years.
Amarin Corporation plc (AMRN) has a market capitalisation of $ 232 Mln as on 29-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Amarin Corporation plc (AMRN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amarin Corporation plc (AMRN) and enter the required number of quantities and click on buy to purchase the shares of Amarin Corporation plc (AMRN).
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland. Address: One Central Plaza, Dublin 2, Ireland, D02 K7K5
The CEO & director of Mr. Patrick J. Holt. is Amarin Corporation plc (AMRN), and CFO & Sr. VP is Mr. Patrick J. Holt.
There is no promoter pledging in Amarin Corporation plc (AMRN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Amarin Corporation plc (AMRN) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.83
|
|
Operating margin(%)
|
-37.73
|
|
Net Margin(%)
|
-40.17
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Amarin Corporation plc (AMRN) was $0 Mln.
$0.01
(
